asx announcement, page-38

The only thing I see is that they want Xtoll, but their exprience and expertise seems to be with chest and heart not anti-inflammatory conditions. This was why Novo wanted Xtoll as that is what they specialse in.
Other reason could be to offset risk, pickup access to easy money, rope in a few more aussies for the risk. I imagine investors a very nervous in US, so might be hard to get funds.
Think CBIO looses 37% in the deal, and they get a chance that they get a drug that might or might not be a winner in about 3 to 5 years.